Principio de precaución en investigación biomédica, seguridad, obligaciones post-investigación y eficacia terapéutica supuesta de las drogas experimentales: Violaciones a la dignidad de los pacientes by Gonorazky, Sergio Eduardo
DebaTe / DEBATE 149
SA
LU
D
 C
o
LEC
T
IV
A
, B
u
en
o
s A
ires, 7
(2
):1
4
9
-1
5
1
, M
ay-A
u
gu
st,
2
0
1
1
 
Universidad Nacional de Lanús | Salud Colectiva | English Edition ISSN 2250-5334
The precautionary principle in biomedical research, safety, 
post-research obligations and alleged therapeutic efficacy of
experimental drugs. Violations of patient dignity
Principio de precaución en investigación biomédica, seguridad, 
obligaciones post-investigación y eficacia terapéutica supuesta de 
las drogas experimentales. Violaciones a la dignidad de los pacientes
It is commonplace to assert that a new
drug must have more therapeutic benefits than
risks associated with taking it. However, from the
selection of the drug that will be placed under
experimental study to the design of the protocol,
from the implementation of a trial to the analysis
of data, from the approval of a drug by the
regulatory body to its sale on the market, the
search for profit on the part of the pharmaceutical
companies comes into tension with the need for
new drugs to prevent and treat diseases. In this
sense, the work of Ugalde and Homedes (1)
provides a thorough and interesting, albeit
worrying, look at the present situation.
So long as the efficacy and safety of
experimental drugs are uncertain, they should be
subject to study in humans according to the
principle of precaution. This approach is
applicable in environmental ethics but must be
extended to include biomedical research as well. 
Ramón Alcoberro (2) explains that the
concept of “precaution” does not necessarily entail
a negative view of technoscience nor a restriction
of research, but it does require being conscious of
the responsibility implied in each and every phase
of the technoscientific process. Making decisions
in conditions that are unknown or uncertain
demands an attitude of precaution, which is
different from one of prevention (when we are
aware of the risks and their probabilities) or of
precautionary prevention (when we are aware of
the risks but not their probabilities) (3). Taking into
account the body of known information and the
information provided by Ugalde and Homedes,
we still have a way to go before the precautionary
principle becomes a rule in the pharmacological
clinical trials tested in humans. 
Examples of the absence of the
precautionary principle include the limited
demands the regulatory agencies place on the
Clinical Trial Data Monitoring Committees
(CTDMC) (4,5), also referred to as Data and
Safety Monitoring Boards (DSMBs) (6). These
entities are defined as: 
[an] external board established by the sponsor to
evaluate, in pre-established intervals of time, the
progress of a clinical study, the data regarding
safety, and the critical points for evaluating
efficacy, in order to recommend whether the
study should be continued, modified, or
stopped. (7) (Italics added)
For the Food and Drug Administration
(FDA), the CTDMC are required solely in
emergency studies in which it is not possible to
take informed consent. The committees are only
recommended in other studies, for example
large, randomized multisite studies which are
intended to prolong life or reduce the risk of a
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major adverse health problem such as a
cardiovascular event or cancer recurrence.
Generally, according to the FDA, the CTDMC are
not necessary in the majority of clinical trials. The
World Health organization (WHo) describes at
length situations in which DSMBs may be
required but it does not portray them as essential.
In Argentina, provision 6677/10 of the National
Administration of Drugs, Food and Medical
Technology (ANMAT, from the Spanish
Administración Nacional de Medicamentos,
Alimentos y Tecnología Médica) states that “the
sponsor may convene an independent data
monitoring board” (7), but currently does not
require it.  In this way, we can find extended
trials aimed at relieving minor symptoms, but that
entail serious and unexpected consequences in
the experimental stage; as the general risk-benefit
analysis rests completely on the sponsor, in the
research process as well as in the determination
of the continuity or the termination of the study,
the analyses and the decisions made are biased. 
on the other hand, the independence
of the CTDMC is controversial because in spite of
being “external to the sponsor,” the members are
appointed and paid by the sponsor. Indeed, in
addition to the safety controls implemented in
clinical trials and grounded in the precautionary
principle, it is necessary to discuss a higher level
of rigor, authority and independence related to
the CTDMC. 
Ugalde and Humedes criticize the
pharmaceutical industry’s claims that the foreign
capital benefits the country in which the research
takes place. The Argentine Chamber of Medical
Specialties (CAEME, from the Spanish Cámara
Argentina de Especialidades Medicinales)
expresses a similar idea in an article entitled,
interestingly enough, “Estudios clínicos, industria
sin chimeneas” [Clinical trials, industry without
chimneys] (8). It may be added that the “canned”
research of sponsors from the industry (in which
the design, protocol and analysis of results are
not carried out by the “researcher”) not only
mistakes the role of a researcher with that of a
recruiter of patients, thereby often redirecting
human resources that could be devoted to
research studies based in local needs, but also, in
some occasions, as happened in the CoMPAS
study highlighted by the authors, turns the
medical professional into a “Body Hunter” (9),
infringing not only the patients' but also the
doctors’ dignity. 
Sponsors as well as many researchers
state that patients recruited for a research study
benefit from better medical care. It is true that, as
a consequence of the research process, patients
have more medical check-ups, but if the patient
was already receiving proper medical care these
added visits do not provide additional benefits.
on the other hand, if the patient was not
receiving proper medical care (as happens in
marginalized populations in which access to
medical care is limited), the patient will be under
more control during the study, but his or her
medical care will truly improve if the researcher
commits to comply with the requirements of
Article 33 of the 2008 Declaration of Helsinki
which states: 
At the conclusion of the study, patients entered
into the study are entitled to be informed about
the outcome of the study and to share any
benefits that result from it, for example, access to
interventions identified as beneficial in the study
or to other appropriate care or benefits. (10)
(Italics added)
This means that beyond the results of
the study, patients should enjoy the same
beneficial accessibility provided by the sponsor
and the researcher after the study is concluded.
The opposite situation would mean that the
patient was used as an instrument (thereby
affecting his or her dignity) for the period of time
that the research was conducted. In the same
publication of the CAEME mentioned previously,
it is stated that: 
…the primary beneficiaries of this [research]
process are the patients because they can access
the most advanced treatments that are not yet
available [and that] those who participate in a
clinical trial have access to services with high
quality standards in terms of medical
interventions and professional care during and
after the development of the study. Moreover,
they receive early and extended access to
medications that may completely change the
prognosis of their disease. (8) (Italics added)
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This confusion between a tested
treatment and an experimental drug (whose
therapeutic efficacy and adverse effects are
unknown), if transmitted to the patient in the
informed consent, would amount to a deception
that could induce inappropriate participation in
the study. Provision 6677/10 of the ANMAT, in
the section regarding to notifications, states that “it
shall not be indicated in an explicit or implicit
way that the product being researched is effective
and/or safe or that it is equivalent to or better than
other existing products” (7). The industry text
cited above evidently transgresses this criterion,
leading to a clear violation of the patient’s dignity.
aCknoWLeDGMenTS
Thank you to the Institutional Research Review Board of the Hospital Privado de Comunidad for giving
me the opportunity to discuss these topics. I release the members of the board from any responsibility in
relation to these comments. 
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